HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

MHRA

Regulatory intelligence
MHRAapproval72% confidence

Clinical trials for medicines: modifying a clinical trial approval

Source: MHRA

Why This Matters

Why this matters: illustrates how regulators handled a comparable approval decision relevant to Eli Lilly.

Regulatory Analysis

Guidance on the various types of modifications that can be made to a clinical trial approval.

Supporting Context

Therapeutic area
Endocrinology · Type 2 Diabetes
Sub-indication
General

Related signal: Lilly's Foundayo shows superior results in Phase 3 trial for type 2 diabetes

Source

View source document

Related Signal

Open signal — Lilly's Foundayo shows superior results in Phase 3 trial for type 2 diabetes
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.